Roberto Hegg

Roberto Hegg

UNVERIFIED PROFILE

Are you Roberto Hegg?   Register this Author

Register author
Roberto Hegg

Roberto Hegg

Publications by authors named "Roberto Hegg"

Are you Roberto Hegg?   Register this Author

19Publications

974Reads

29Profile Views

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

N Engl J Med 2018 11 20;379(22):2108-2121. Epub 2018 Oct 20.

From the Barts Cancer Institute, Queen Mary University of London, London (P.S.); Perlmutter Cancer Center, New York University School of Medicine, New York (S.A.); the Department of Medicine, University of California, San Francisco, San Francisco (H.S.R.), and Genentech, South San Francisco (L.M., S.Y.C., R.F.) - both in California; University Hospital Heidelberg, Heidelberg, Germany (A.S.); Centro de Pesquisa em Oncologia, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre (C.H.B.), and the University of São Paulo, São Paulo (R.H.) - both in Brazil; Aichi Cancer Center Hospital, Nagoya, Japan (H.I.); the Department of Medical Oncology, Institut Curie, Paris (V.D.); Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea (S.-A.I.); Florida Cancer Specialists and Research Institute, New Port Richey (G.S.W.); Roche, Basel, Switzerland (V.H., A.H.); Dana-Farber Cancer Institute, Boston (E.P.W.); Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia (S.L.); and the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore (L.A.E.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1809615
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1809615DOI Listing
November 2018

First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial.

J Clin Oncol 2018 10 14;36(28):2826-2835. Epub 2018 Aug 14.

Mothaffar Rimawi and C. Kent Osborne, Baylor College of Medicine, Houston, TX; Jean-Marc Ferrero, Centre Antoine Lacassagne, Nice, France; Juan de la Haba-Rodriguez, Reina Sofía Hospital, University of Córdoba, Córdoba, Spain; Christopher Poole, University Hospitals Coventry; Christopher Poole, Warwickshire National Health Service Trust, Coventry, United Kingdom; Sabino De Placido and Grazia Arpino, University Federico II, Naples, Italy; Roberto Hegg, Hospital Pérola Byington; Roberto Hegg, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; and Valerie Easton and Christine Wohlfarth, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.7863DOI Listing
October 2018

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.

J Clin Oncol 2018 03 15;36(8):741-748. Epub 2017 Dec 15.

Stephen R.D. Johnston, The Royal Marsden NHS Foundation Trust, London; Lisa S. Williams, Novartis Pharmaceuticals UK Limited, Frimley, United Kingdom; Roberto Hegg, Centro de Referência da Saúde da Mulher; Sergio D. Simon, Hospital Israelita Albert Einstein, São Paulo, Brazil; Seock-Ah Im, Seoul National University College of Medicine, Seoul; In Hae Park, National Cancer Center, Gyeonggi-do, Korea; Olga Burdaeva, Regional Oncology Dispensary, Arkhangelsk; Sergei Tjulandin, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; Galina Kurteva, University Cancer Center Hospital, Sofia, Bulgaria; Michael F. Press, University of Southern California, Los Angeles, CA; Hiroji Iwata, Aichi Cancer Center Hospital, Aichi, Japan; Sarah Kenny, Severine Sarp, and Miguel A. Izquierdo, Novartis Pharma AG, Basel, Switzerland; and William J. Gradishar, Northwestern University, Chicago, IL.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.7824
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.7824DOI Listing
March 2018

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.

Int J Gynecol Cancer 2017 01;27(1):50-58

*Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada; †Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, and Alliance Pour la Recherche en Cancérologie, Paris, France; ‡Chemotherapy Department of State Budgetary Healthcare Institution, Clinical Oncology Dispensary #1, Krasnodar Region Ministry of Healthcare, Krasnodar, Russia; §Gynecologic Oncology Department, Sheba Medical Center, Tel Hashomer, Israel; ∥University Hospital 12 de Octubre, Madrid, Spain; ¶Medical Department, Gustave Roussy, Villejuif, France; #Department of Clinical Oncology, Oncology Center Prof. F. Lukaszczyka, Bydgoszcz, Poland; **Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece; ††Ente Ospedaliero Ospedali Galliera, Genoa, Italy; ‡‡Riga East University Hospital, Latvian Oncology Centre, Riga, Latvia; §§Medical Oncology Department, MD Anderson Cancer Center Madrid, Madrid, Spain; ∥∥Pérola Byington Hospital/Faculty of Medicine University of São Paulo, São Paulo, Brazil; ¶¶Medical Oncology Department, Centre François Baclesse, Caen, France; ##Policlinico Sant'Orsola-Malpighi, Bologna, Italy; ***Division of Gynecology and Obstetrics, Department of Experimental and Clinical Medicine, University of Pisa, Pisa, Italy; †††Global Medical Affairs, F. Hoffmann-La Roche Ltd, Basel, Switzerland; and ‡‡‡Division of Medical Gynecologic Oncology, European Institute of Oncology and University of Milano-Bicocca, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000836DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5181120PMC
January 2017

Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.

J Clin Oncol 2015 Jan 2;33(2):141-8. Epub 2014 Sep 2.

John R. Mackey, Cross Cancer Institute; Francois Thireau and Helena Fung, Translational Research in Oncology, Edmonton; Marc Webster, Tom Baker Cancer Centre, Calgary, Alberta; Karen A. Gelmon, British Columbia Cancer Agency, Vancouver, British Columbia; Sunil Verma, Sunnybrook Health Sciences Center; Lorinda Simms, Eli Lilly, Toronto, Ontario, Canada; Manuel Ramos-Vazquez, Centro Oncológico de Galicia "José Antonio Quiroga y Piñeiro," A Coruña; Miguel Martin, Instituto de Investigación Sanitaria Gregorio Marañon, Universidad Complutense, Madrid, Spain; Oleg Lipatov, Republican Clinical Oncology Dispensary, Bashkortostan Republic Ministry of Health, Ufa; Dmitriy Krasnozhon, Leningrad Regional Oncology Dispensary, Leningrad; Vladimir Semiglazov, Institute of Oncology N.N. Petrov; Alexey Manikhas, City Clinical Oncology Dispensary, St Petersburg; Vera Gorbunova, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; Nicole McCarthy, ICON Cancer Care Wesley, Brisbane, Queensland, Australia; Gottfried E. Konecny, University of California Los Angeles, Los Angeles, CA; Roberto Hegg, Hospital Pérola Byigton Centro de Referência da Saúde da Mulher, Sao Paulo, Brazil; Dany Abi Gerges, Middle East Institute of Health, Bsalim, Lebanon; Marc Buyse, International Drug Development Institute, Louvain-la-Neuve, Belgium; and Ayman Ibrahim, ImClone Systems, Bridgewater, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.1513DOI Listing
January 2015

Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study.

Cancer Chemother Pharmacol 2009 Jan 26;63(2):281-7. Epub 2008 Mar 26.

Lipid Metabolism Laboratory, Heart Institute (InCor), University of São Paulo Medical School Hospital, Av. Dr. Eneas de Carvalho Aguiar, 44, 1 degrees subsolo, São Paulo 05403-000, Brazil.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s00280-008-0738
Web Search
http://link.springer.com/10.1007/s00280-008-0738-2
Publisher Site
http://dx.doi.org/10.1007/s00280-008-0738-2DOI Listing
January 2009

Uptake of a cholesterol-rich emulsion by breast cancer.

Gynecol Oncol 2002 Jun;85(3):493-7

Department of Gynecology and Lipid Metabolism Laboratory of The Heart Institute (InCor), University of São Paulo, São Paulo, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1006/gyno.2002.6654DOI Listing
June 2002